The FDA recently OK'd two of Royal Philips' AI-enabled devices, including the industry's first automated tool for segmental wall motion heart scoring, the company said June 4.
With the help of AI, the company's EPIQ CVx and Affiniti CVx ultrasound systems speed up cardiac ultrasound analysis and reduce the burden on echocardiography labs, Philips said in a news release.
Cardiovascular ultrasounds are a common test to check the heart's structure and function, and they help in early cardiac disease diagnoses. Amid increases in high acuity cases and patient volumes, cardiologists read hundreds of echocardiography exams every day, according to Roberto Lang, MD, director of the University of Chicago Medicine's noninvasive cardiac imaging lab.
In the release, Dr. Lang said these new devices can offer results within seconds.
"Trained on anonymized patient data sets from real-life clinical environments, the AI features integrated across Philips cardiovascular ultrasound systems help improve the quality and reproducibility of cardiac imaging and enhance operator and departmental efficiency," the release said.